User:Mr. Ibrahem/Nabumetone
 | |
| Clinical data | |
|---|---|
| Trade names | Relafen, Relifex, Gambaran, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a692022 |
| Routes of administration | By mouth |
| Drug class | NSAID[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | > 99% (active metabolite) |
| Metabolism | Liver, to active metabolite 6-methoxy-2-naphthylacetic acid; 6-MNA |
| Elimination half-life | 23 hours (active metabolite) |
| Excretion | Kidney |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C15H16O2 |
| Molar mass | 228.291 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID), used to treat inflammation in conditions such as osteoarthritis and rheumatoid arthritis.[1] Use is recommended for a short a duration as possible.[3]
Common side effects include abdominal pain, constipation, dizziness, swelling, headache, rash, and ringing in the ears.[1] Other side effects may include kidney problems, heart attacks, gastrointestinal bleeding, high blood pressure, anaphylaxis, and heart failure.[1] Use during the later part of pregnancy may harm the baby.[2] It works by blocking COX-1 and COX-2.[1]
Nabumetone was approved for medical use in the United States in 1991.[1] In the United Kingdom 4 weeks of treatment costs the NHS about £7.[2] This amount in the United States costs about 26 USD.[4]
References[edit]
- ^ a b c d e f g "Nabumetone Monograph for Professionals". Drugs.com. Archived from the original on 7 March 2021. Retrieved 11 November 2021.
- ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1194. ISBN 978-0857114105.
- ^ "DailyMed - NABUMETONE tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 13 November 2021. Retrieved 11 November 2021.
- ^ "Nabumetone Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 21 December 2019. Retrieved 11 November 2021.